Search Result

Results for "

GLP-1R agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLP Receptor (85) Akt (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (8) Arrestin (2) Autophagy (8) Bcl-2 Family (8) Cytochrome P450 (1) Drug Intermediate (1) Fluorescent Dye (2) GCGR (45) Insulin Receptor (10) Isotope-Labeled Compounds (3) Neuropeptide Y Receptor (4) p38 MAPK (8) Phosphodiesterase (PDE) (1) Potassium Channel (1) PTHR (2) α-synuclein (8)
By Research Areas:	Cancer (9) Cardiovascular Disease (8) Endocrinology (2) Infection (1) Inflammation/Immunology (13) Metabolic Disease (109) Neurological Disease (11)

116

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GLP Receptor

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-112185

Orforglipron 1 Publications Verification LY3502970; GLP-1 receptor agonist 1	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .

HY-125824

Danuglipron 4 Publications Verification PF-06882961	GCGR	Metabolic Disease
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-164535

Maridebart cafraglutide AMG 133	Antibody-Drug Conjugates (ADCs) GLP Receptor Insulin Receptor	Metabolic Disease
Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC₅₀ values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC₅₀ values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-121835

GLP-1R agonist 2	GCGR	Metabolic Disease
GLP-1R agonist 2 (compound 2) is an effective *GLP-1R* agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of *GLP-1R. GLP-1R* agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity .

HY-153865

Lotiglipron PF-07081532	GLP Receptor	Metabolic Disease
Lotiglipron (PF-07081532) is an orally active *GLP-1R* agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .

HY-160734

Aleniglipron GSBR-1290	GLP Receptor	Metabolic Disease
Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC₅₀ value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of *GLP-1R* without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity .

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a GLP-1 analog agonist peptide. AMG133 peptide potently activates GLP-1R, and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload can be used for the synthesis of AMG 133 (HY-164535) .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-177295

Naperiglipron LY3549492	GLP Receptor Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC₅₀ of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC₅₀: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research .

HY-112185A

Orforglipron hemicalcium hydrate 1 Publications Verification LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .

HY-P10736A

AMG133 peptide payload TFA	GCGR	Metabolic Disease
AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 (HY-164535) .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S3

Semaglutide-13C6,15N TFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Metabolic Disease
Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-175701

CT-996 RO7795081; RG6652	Arrestin GLP Receptor	Metabolic Disease
CT-996 is an orally active GLP-1RA agonist with an EC₅₀ of 0.49 nM. CT-996 reduces the recruitment of β-arrestin and the internalization of *GLP-1R*. CT-996 suppresses postprandial blood glucose in mice expressing human GLP-1 receptors and enhances glucose-stimulated insulin secretion (GSIS) in obese monkeys during intravenous glucose challenge. CT-996 can be used for the research of type 2 diabetes (T2D) and obesity .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC₅₀ of 0.57 nM for *GLP-1R* and an EC₅₀ of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .

HY-112679

GLP-1 receptor agonist 2	GCGR	Inflammation/Immunology
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor *(GLP-1R)* agonist .

HY-145458

PF-06954522 GLP-1 receptor agonist 9	GLP Receptor	Metabolic Disease
PF-06954522 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06954522 is applicable to research related to type 2 diabetes .

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-45894

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu Semaglutide side chain	GLP Receptor	Metabolic Disease Inflammation/Immunology
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-116819

VU0453379	GCGR	Neurological Disease Metabolic Disease
VU0453379 is a blood-brain barrier permeable *GLP-1R* positive allosteric modulator (PAM) with an EC₅₀ value of 1.3 μM. VU0453379 potentiates the actions of endogenous GLP-1 and synthetic peptide agonists, and promotes GLP-1 receptor internalization. VU0453379 stimulates insulin secretion from primary mouse islets. VU0453379 enhances the function of endogenous *GLP-1R* and reverses catalepsy in animal models. VU0453379 is useful for research on Parkinson's disease and type 2 diabetes .

HY-145412

GLP-1 receptor agonist 7	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 7 (Compound 130b) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC₅₀ of ≤ 0.2 nM. GLP-1 receptor agonist 7 can be used to study diseases related to the GLP-1 receptor (particularly type 2 diabetes) .

HY-144034

GLP-1R agonist 3	GLP Receptor	Metabolic Disease
GLP-1R agonist 3 is a potent agonist of *GLP-1R. GLP-1R* agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease Inflammation/Immunology
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant *GLP-1R* agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .

HY-P10716

Exendin-P5	GLP Receptor	Metabolic Disease
Exendin-P5 is a selective agonist that targets the *GLP-1R. Exendin-P5 promotes rapid activation of G proteins by transient interactions with the transmembrane domain of GLP-1R, enhancing its potency in G protein*-mediated signaling and accelerating cAMP production. This mechanism suggests the potential application of Exendin-P5 in the study of metabolic diseases .

HY-N2452

Cochinchinenin C	GLP Receptor	Cardiovascular Disease Infection Metabolic Disease
Cochinchinenin C is a *GLP-1R* agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .

HY-163996

DD202-114	GLP Receptor Potassium Channel Cytochrome P450	Metabolic Disease
DD202-114 is a potent and selective *GLP1R* agonist. DD202-114 inhibits hERG with an IC₅₀ of 15.9 μM. DD202-114 exhibits strong CYP2C8 inhibition with an IC₅₀ of 0.22 μM. DD202-114 promotes cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential to be used in the study of type 2 diabetes mellitus (T2DM) and obesity .

HY-147625

GLP-1R agonist 12	GLP Receptor	Metabolic Disease
GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research .

HY-148212

GLP-1R agonist 17	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1R agonist 17 (Compound example 232) is a GLP-1 receptor agonist. GLP-1R agonist 17 shows excellent agonism on a GLP-1 receptor. GLP-1R agonist 17 can be used for the research of cardiovascular metabolic diseases .

HY-144035

GLP-1R agonist 4	GCGR	Metabolic Disease Inflammation/Immunology
GLP-1R agonist 4 is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-129657

GLP-1 receptor agonist 4	GCGR	Metabolic Disease
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC₅₀ of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .

HY-178769

GLP-1R agonist 36	GLP Receptor	Metabolic Disease
GLP-1R agonist 36 (Compound 53) is a *GLP-1R* agonist with a total of four isomers. GLP-1R agonist 36 can be used for the studies of diabetes and obesity.

HY-178768

GLP-1R agonist 35	GLP Receptor	Metabolic Disease
GLP-1R agonist 35 (Compound 111-2) is a GLP-1R agonist with an EC₅₀ of 0-10 nM. GLP-1R agonist 36 can be used for the studies of diabetes and obesity .

HY-147628

GLP-1R agonist 15	GLP Receptor	Metabolic Disease
GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist .

HY-147623

GLP-1R agonist 10	GLP Receptor	Metabolic Disease
GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC₅₀ of 0.051 nM .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

HY-161915

GLP-1R agonist 23	GLP Receptor	Metabolic Disease
GLP-1R agonist 23 (Example 376) is a *GLP-1R* agonist with an EC₅₀ of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research .

HY-125824A

Danuglipron tromethamine PF-06882961 tromethamine	GCGR	Metabolic Disease
Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research .

HY-P3539

Exendin-4 (3-39)	GCGR	Neurological Disease Endocrinology
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-168481

GLP-1R agonist 27	GLP Receptor	Metabolic Disease
GLP-1R agonist 27 (compound 21) is a potent and orally active *GLP-1R* agonist. GLP-1R agonist 27 promots cyclic adenosine monophosphate (cAMP) accumulation. GLP-1R agonist 27 reduces blood glucose levels and food intake. GLP-1R agonist 27 has the potential for the research of obesity and type 2 diabetes mellitus (T2DM) .

HY-147622

GLP-1R agonist 9	GCGR	Metabolic Disease
GLP-1R agonist 9 (Compound 96) is a *GLP-1R* agonist with EC₅₀ values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively .

Cat. No.	Nombre del producto	Type

HY-164535

Maridebart cafraglutide

AMG 133

Fluorescent Dye

Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC₅₀ values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC₅₀ values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .

Cat. No.	Nombre del producto	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P10736

AMG133 peptide payload	GCGR	Metabolic Disease
AMG133 peptide payload is a GLP-1 analog agonist peptide. AMG133 peptide potently activates GLP-1R, and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload can be used for the synthesis of AMG 133 (HY-164535) .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P10736A

AMG133 peptide payload TFA	GCGR	Metabolic Disease
AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 (HY-164535) .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-145632

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) is a *GLP-1R/GCGR* dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC₅₀ of 0.57 nM for *GLP-1R* and an EC₅₀ of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-45894

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu Semaglutide side chain	GLP Receptor	Metabolic Disease Inflammation/Immunology
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting *glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)* dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease Inflammation/Immunology
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant *GLP-1R* agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .

HY-P10716

Exendin-P5	GLP Receptor	Metabolic Disease
Exendin-P5 is a selective agonist that targets the *GLP-1R. Exendin-P5 promotes rapid activation of G proteins by transient interactions with the transmembrane domain of GLP-1R, enhancing its potency in G protein*-mediated signaling and accelerating cAMP production. This mechanism suggests the potential application of Exendin-P5 in the study of metabolic diseases .

HY-145632A

Pemvidutide TFA ALT-801 TFA	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) TFA is a *GLP-1R/GCGR* dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

HY-P3539

Exendin-4 (3-39)	GCGR	Neurological Disease Endocrinology
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of *GLP-1R* (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-13443F2

Exendin-4, Cy5 labeled Exendin-4-Cys(Cy5)	Fluorescent Dye	Metabolic Disease
Exendin-4, Cy5-labeled (Exendin-4-Cys(Cy5)) is a covalently linked Cy5 fluorescent group to Exendin-4 (HY-13443), a GLP-1 receptor agonist. Exendin-4, Cy5-labeled enables the visualization imaging of β cells in vivo, especially for evaluating the expression dynamics of GLP-1R in type 2 diabetes models .

HY-P11262

GUB021794	GLP Receptor	Metabolic Disease
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC₅₀ value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC₅₀ value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .

HY-P4146B

Survodutide sodium BI 456906 sodium	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) sodium is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide sodium, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide sodium has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4386

(Asp28)-Exenatide	GLP Receptor	Metabolic Disease
(Asp28)-Exenatide is a degradation product of exenatide (HY-13443). (Asp28)-Exenatide can be used as a *GLP-1R* agonist .

HY-P11279

TC2	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, *GLP-1R, GcgR, and Y2R* with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

HY-P11275

TC4	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, *GLP-1R, GcgR, and Y2R* with IC₅₀ values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .

HY-P11670

Linvixdutide	GLP Receptor	Metabolic Disease
Linvixdutide is a glucagon and glucagon-like peptide 1 receptor (GLP-1R) agonist with anti-obesity effects .

HY-P11044

GEP12	GCGR Neuropeptide Y Receptor	Metabolic Disease
GEP12 is a *GLP-1R/Y1-R/Y2-R* tri-receptor agonist peptide with an EC₅₀ of 17.3 nM and an IC₅₀ of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .

HY-P10842

d-GLP-2 E33A	GLP Receptor Akt	Metabolic Disease Inflammation/Immunology
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC₅₀ of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on *GLP-1R*. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .

HY-P5161

FC382K10W15	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 is a glucagon analogue and *GLP-1R/GCGR* agonist. FC382K10W15 can be used in type 2 diabetes research .

HY-P5161A

FC382K10W15 TFA	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and *GLP-1R/GCGR* agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive *GLP-1R* agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118F4

Semaglutide-FITC Semaglutide-Lys(FITC)	Fluorescent Dye GLP Receptor	Metabolic Disease
Semaglutide-FITC (Semaglutide-Lys(FITC)) is a FITC-labeled Semaglutide (a *GLP-1R* agonist) (HY-114118). Semaglutide-FITC can be used to directly track the distribution, cellular uptake, and transmembrane transport process of vesicles through techniques such as fluorescence imaging and flow cytometry. Semaglutide-FITC can be employed to study the movement and penetration ability of mixed vesicles in porcine intestinal mucus in vitro .

HY-P11487

UTG-4	GLP Receptor GCGR	Cardiovascular Disease Metabolic Disease
UTG-4 is a *GLP-1R, GIPR, and GCGR* agonist with EC₅₀ values of 126.3 pM, 29.2 pM, and 250.2 pM, respectively. UTG-4 binds to HSA (K_d = 14.6 μM). UTG-4 effectively alleviates endothelial-mesenchymal transition. UTG-4 promotes weight loss, inhibits food intake, improves glucose tolerance, and has a significant anti-atherosclerotic effect .

HY-P11673

Zabopegdutide	GLP Receptor	Metabolic Disease
Zabopegdutide is a glucagon and glucagon-like peptide 1 (GLP-1) receptor agonist. Zabopegdutide can be used for the study of obesity .

HY-P11667

Erzemdutide	GLP Receptor	Metabolic Disease
Erzemdutide is a glucagon and glucagon-like peptide 1 (GLP-1) receptor agonist. Erzemdutide can be used for the study of obesity .

HY-P11672

Poterepatide HDM1005	GLP Receptor	Metabolic Disease
Poterepatide (HDM1005) is a long-acting *GLP-1R/GIPR* peptide dual agonist. Poterepatide exhibits potent activity on both GLP-1 and GIP receptors. Poterepatide can be used for the study of obesity and type 2 diabetes .

HY-P11664

Anvoglutide	GLP Receptor	Metabolic Disease Inflammation/Immunology
Anvoglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with antidiabetic and obesity effects .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-N2452

Cochinchinenin C	other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	GLP Receptor
Cochinchinenin C is a *GLP-1R* agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .

Cat. No.	Nombre del producto	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-172836S

GLP-1 receptor agonist 17-d3
GLP-1 receptor agonist 17-d₃ (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

GLP-1R agonists

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products